Naglazyme (Galsulfase)

Galsulfase, the active ingredient in Naglazyme, is an enzyme replacement therapy presented as a solution for injection for intravenous use. It replaces deficient N‑acetylgalactosamine‑4‑sulfatase activity, facilitating degradation of dermatan sulfate in patients with mucopolysaccharidosis type VI (Maroteaux‑Lamy syndrome).

GNH USA supplies Naglazyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing products sourced from the European Union market under strict quality standards. The company ensures reliable access for rare‑disease therapies through regulated cold‑chain logistics.

Naglazyme is used in enzyme replacement therapy for lysosomal storage disorders.

- Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): reduces accumulation of dermatan sulfate, helping maintain organ function. - Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): improves mobility and respiratory capacity. - Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): slows progression of skeletal abnormalities and supports cardiac health.

Common Side Effects: - Infusion-related reactions: flushing, chills, or rash. - Fever or chills. - Headache. - Nausea or vomiting. - Abdominal pain. - Mild fatigue.

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity. - Significant liver enzyme elevation. - Thrombocytopenia. - Pulmonary hypertension. - Renal impairment. - Severe respiratory distress.

Naglazyme requires careful monitoring due to its biologic nature and potential immunogenicity.

- Infusion reactions: observe patients during and after administration. - Liver function: assess baseline and periodic liver enzymes. - Cardiac status: monitor for signs of pulmonary hypertension. - Antibody formation: test for neutralizing antibodies if clinical response wanes. - Hypersensitivity: avoid in patients with known allergy to Galsulfase or any component of the formulation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Naglazyme may interact with other biologic agents and vaccines.

Major Interactions (Avoid): - Concurrent enzyme replacement therapies: may increase immunogenic response. - Live attenuated vaccines: reduced efficacy; avoid administration during treatment.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early infusion reactions. - Systemic corticosteroids: could diminish antibody formation. - Other immunosuppressants: heightened infection risk. - Anticoagulants: monitor for bleeding if infusion causes vascular irritation.